NONINVASIVE METHODS IN EVALUATION OF INFLAMMATORY BOWEL DISEASE: WHERE DO WE STAND NOW? AN UPDATE


Turkay C., KASAPOĞLU B.

CLINICS, vol.65, no.2, pp.221-231, 2010 (Peer-Reviewed Journal) identifier identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 65 Issue: 2
  • Publication Date: 2010
  • Doi Number: 10.1590/s1807-59322010000200015
  • Journal Name: CLINICS
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.221-231
  • Keywords: Inflammatory bowel disease, Diagnosis, Serology, Fecal markers, SACCHAROMYCES-CEREVISIAE ANTIBODIES, FECAL CALPROTECTIN LEVELS, RECTAL NITRIC-OXIDE, SEROLOGICAL MARKERS, CROHNS-DISEASE, INTESTINAL INFLAMMATION, LACTOFERRIN, NEUTROPHIL, EXCRETION, DIAGNOSIS

Abstract

The inflammatory bowel diseases, consisting of Crohn's disease, ulcerative colitis and indeterminate colitis, are distinguished by idiopathic and chronic inflammation of the digestive tract. The distinction between inflammatory bowel diseases and functional bowel disorders, such as irritable bowel syndrome, can be complex because they often present with similar symptoms. Rapid and inexpensive noninvasive tests that are sensitive, specific and simple are needed to prevent patient discomfort, delay in diagnosis, and unnecessary costs. None of the current commercially available serological biomarker tests can be used as a stand-alone diagnostic in clinics. Instead, these are used as an adjunct to endoscopy in diagnosis and prognosis of the disease. Along these lines fecal lactoferrin and calprotectin tests seem to be one step further from other tests with larger number of studies, higher sensitivity and specificity and wider availability.